Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia
This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Future efforts should focus on improving ASO delivery and knockdown efficiency to maximize therapeutic benefit.
Authors
- Evan Lind (ORCID: https://orcid.org/0000-0001-7026-2012)
- Alexey S. Revenko (ORCID: https://orcid.org/0000-0002-4863-362X)
- Hadi Maazi (ORCID: https://orcid.org/0000-0002-8979-3769)
- Angelica Tolentino
- Katia G. de Oliveira Rebola (ORCID: https://orcid.org/0000-0001-5446-3922)
- Sokchea Khou (ORCID: https://orcid.org/0000-0002-5386-9856)
- Haijiao Zhang (ORCID: https://orcid.org/0000-0002-0749-9866)
- H. J. Lin
- Anupriya Agarwal
- Ariel Dean
Institutions
- Oregon Health & Science University (US)
- Ionis Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-03-09
- DOI
- https://doi.org/10.3389/fonc.2026.1659341
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cancer Research Institute
- Oregon Health and Science University
- National Heart, Lung, and Blood Institute
- National Cancer Institute